Loading...
•
Jun 30, 2024
Pacira Q2 2024 Earnings Report
Pacira's financial performance remained strong, driven by solid sales across all three opioid-sparing products, balance sheet strengthening, and leadership realignment.
Key Takeaways
Pacira BioSciences reported a total revenue of $178.0 million for Q2 2024, with net income reaching $18.9 million, or $0.39 per share (diluted). The company is focused on maximizing the benefit of separate EXPAREL reimbursement for outpatient procedures with the implementation of NOPAIN in January 2025.
Total revenues reached $178.0 million.
EXPAREL net product sales were $136.9 million.
Net income was $18.9 million, or $0.39 per share (diluted).
Adjusted EBITDA amounted to $62.1 million.
Revenue by Segment
Forward Guidance
Pacira is reiterating its full-year 2024 financial guidance.
Positive Outlook
- Total revenue of $680 million to $705 million.
- Non-GAAP gross margin of 74% to 76%.
- Non-GAAP R&D expense of $70 million to $80 million.
- Non-GAAP SG&A expense of $245 million to $265 million.
- Stock-based compensation of $50 million to $55 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...